Development and characterization of reference materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 genetic testing

Journal of Molecular Diagnostics

Volumn 11, Issue 6, 2009, Pages 553-561

  Barker, Shannon D ^a   Bale, Sherri ^b   Booker, Jessica ^c   Buller, Arlene ^d   Das, Soma ^e   Friedman, Kenneth ^f   Godwin, Andrew K ^g   Grody, Wayne W ^h   Highsmith, Edward ⁱ   Kant, Jeffery A ^j   Lyon, Elaine ^k   Mao, Rong ^k   Monaghan, Kristin G ^l   Payne, Deborah A ^m   Pratt, Victoria M ^d   Schrijver, Iris ⁿ   Shrimpton, Antony E ^o   Spector, Elaine ^p   Telatar, Milhan ^q   Toji, Lorraine ^r   Weck, Karen ^c   Zehnbauer, Barbara ^a,s   Kalman, Lisa V ^a   more..

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b GENEDX   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f LABORATORY CORPORATION OF AMERICA   (United States)

^g FOX CHASE CANCER CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ MAYO CLINIC   (United States)

^j UNIVERSITY OF PITTSBURGH   (United States)

^k ARUP LABORATORIES   (United States)

^l HENRY FORD HOSPITAL   (United States)

^m UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁿ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^p Children's Hospital Colorado   (United States)

^q Specialty Laboratories   (United States)

^r Laboratory of Molecular and Cellular Biology of Hematopoiesis   (United States)

^s WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; NEUROSERPIN; PROTEIN RET;

ARTICLE; CONTROLLED STUDY; GENE; GENOTYPE; HUMAN; HUMAN CELL; MTHFR GENE; NUCLEOTIDE SEQUENCE;

EID: 70350456263     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2009.090078     Document Type: Article

References (52)

1. Dequeker E, Ramsden S, Grody WW, Stenzel T, Barton DE: Quality control in molecular genetic testing. Nat Rev 2001, 2:717-723 (Pubitemid 33674793)
2. Emons H, Fajgelj A, van der Veen AMH, Watters R: New definitions on reference materials. Accred Qual Assur 2006, 10:576-578
3. Emons H, Linsinger TPL, Gawlik BM: Reference materials: terminology and use. Can't one see the forest for the trees? Trends Anal Chem 2004, 23:442-449
4. Walker R, Lumley I: Pitfalls in terminology and use of reference materials. Trends Anal Chem 1999, 18:594-616 (Pubitemid 29418016)
5. Winn-Deen ES: Standards and controls for genetic testing. Cancer Biomark 2005, 1:217-220
6. Chen B, O'Connell CD, Boone DJ, Amos JA, Beck JC, Chan MM, Farkas DH, Lebo RV, Richards CS, Roa BB, Silverman LM, Barton DE, Bejjani BA, Belloni DR, Bernacki SH, Caggana M, Charache P, Dequeker E, Ferreira-Gonzalez A, Friedman KJ, Greene CL, Grody WW, Highsmith WE Jr, Hinkel CS, Kalman LV, Lubin IM, Lyon E, Payne DA, Pratt VM, Rohlfs E, Rundell CA, Schneider E, Willey AM, Williams LO, Willey JC, Winn-Deen ES, Wolff DJ: Developing a sustainable process to provide quality control materials for genetic testing. Genet Med 2005, 7:534-549 (Pubitemid 41566480)
7. Pratt VM, Caggana M, Bridges C, Buller AM, DiAntonio L, Highsmith WE, Holtegaard LM, Muralidharan K, Rohlfs EM, Tarleton J, Toji L, Barker SD, Kalman LV: Development of genomic reference materials for cystic fibrosis genetic testing. J Mol Diagn 2009, 11:186-193 (Pubitemid 350287158)
8. Kalman L, Johnson MA, Beck J, Berry-Kravis E, Buller A, Casey B, Feldman GL, Handsfield J, Jakupciak JP, Maragh S, Matteson K, Muralidharan K, Richie KL, Rohlfs EM, Schaefer F, Sellers T, Spector E, Richards CS: Development of genomic reference materials for Huntington disease genetic testing. Gen Med 2007, 9:719-723 (Pubitemid 350287158)
9. Amos Wilson A, Pratt VM, Phansalkar A, Muralidharan K, Highsmith WE, Beck JC, Bridgeman S, Courtney EM, Epp L, Ferreira-Gonzalez A, Hjelm NL, Holtegaard LM, Jama MA, Jakupciak JP, Johnson MA, Labrousse P, Lyon E, Prior TW, Richards CS, Richie KL, Roa BB, Rohlfs EM, Sellers T, Sherman SL, Siegrist KA, Silverman LM, Wiszniewska J, Kalman LV, Fragile Xperts Working Group of AMP: Consensus characterization of 16 FMR1 reference materials: a consortium study. J Mol Diagn 2008, 10:2-12
10. Kalman L, Amos Wilson J, Buller A, Dixon J, Edelmann L, Geller L, Highsmith WE, Holtegaard L, Kornreich R, Rohlfs EM, Payeur TL, Sellers T, Toji L, Muralidharan K: Development of genomic DNA reference materials for genetic testing of disorders common in people of Ashkenazi Jewish descent. J Mol Diagn, in press
11. Ilhan N, Kucuksu M, Kaman D, Ilhan N, Ozbay Y: The 677 C/T MTHFR polymorphism is associated with essential hypertension, coronary artery disease, and higher homocysteine levels. Arch Med Res 2008, 39:125-130 (Pubitemid 350192019)
12. Frederiksen J, Juul K, Grande P, Jensen GB, Schroeder TV, Tybjaerg-Hansen A, Nordestgaard BG: Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study. Blood 2004, 104:3046-3051 (Pubitemid 39507118)
13. Blom HJ: Genetic determinants of hyperhomocysteinemia: the roles of cystathionine beta-synthase and 5,10-methylenetetrahydrofolate reductase. Eur J Pediatr 2000, 159(Suppl 3):S208-S212
14. Zee RYL, Mora S, Cheng S, Erlich HA, Lindpaintner K, Rifai N, Buring JE, Ridker PM: Homocysteine, 5,10-Methylenetetrahydrofolate reductase 677C>T polymorphism, nutrient intake, and incident cardiovascular disease in 24,968 initially healthy women. Clin Chem 2007, 53:845-851
15. Brown NM, Pratt VM, Buller A, Pike-Buchanan L, Redman JB, Sun W, Chen R, Crossley B, McGinniss MJ, Quan F, Strom CM: Detection of 677CT/1298AC "double variant" chromosomes: implications for interpretation of MTHFR genotyping results. Genet Med 2005, 7:278-282
16. 1-antitrypsin S and Z mutations. Genet Testing 2005, 9:185-189
17. Fregonese L, Stolk J: Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis 2008, 3:16
18. Cox DW, Levinson H: Emphysema of early onset associated with a complete deficiency of alpha-1 antitrypsin (null homozygotes). Am Rev Respir Dis 1988, 137:317-375
19. Turina GM, Barker AF, Brantly ML: Clinical features of individuals with PiSZ phenotype of alpha-1-antitrypsin deficiency. Am J Respir Crit Care Med 1996, 154:1718-1725
20. Marini F, Falchetti A, Del Monte F, Carbonell Sala S, Tognarini I, Luzi E, Brandi ML: Multiple endocrine neoplasia type 2. Orphanet J Rare Dis 2006, 1:45
21. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993, 363:458-460 (Pubitemid 23179393)
22. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993, 2:851-856 (Pubitemid 23216611)
23. Edery P, Eng C, Munnich A, Lyonett S: RET in human development and oncogenesis. Bioassays 1997, 19:389-395
24. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Mulligan LM: The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: international RET mutation consortium analysis. JAMA 1996, 276:1575-1579 (Pubitemid 26384740)
25. Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JB, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H, Neumann HPH, Thibodeau SN, Ponder BAJ: Specific mutations of the RET protooncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 1994, 6:70-74 (Pubitemid 24191916)
26. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Birch JM, Lindblom A, Stoppa-Lyonnet D, Bignon Y, Borg A, Hamann U, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, Cannon-Albright LA, Schofield A, Zelada-Hedman M, Breast Cancer Linkage Consortium: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998, 62:676-689
27. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Nat Cancer Inst 2002, 94:1365-1372 (Pubitemid 35154141)
28. Robles-Diaz L, Goldfrank DJ, Kauff ND, Robson M, Offit K: Hereditary ovarian cancer in Ashkenazi Jews. Fam Cancer 2004, 3:259-264 (Pubitemid 39491743)
29. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72:1117-1130 (Pubitemid 36530000)
30. Roa BB, Boyd AA, Volcik K, Richards CS: Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996, 14:185-187 (Pubitemid 26338801)
31. Struewing JP, Hartage P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997, 336:1401-1408 (Pubitemid 27208598)
32. Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, Hampel H, Borgen P, Brown K, Skolnick M, Shattuck-Eidens D, Jhanwar S, Goldgar D, Offit K: Recurrent BRCA2 6174delT mutation in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996, 13:126-128 (Pubitemid 126528244)
33. Beck JC, Beiswanger CM, John EM, Satraiano WD: Successful transformation of cryopreserved lymphocytes: a resource for epidemiological studies. Cancer Epidemiol Biomarkers Prev 2001, 10:551-554
34. Bernacki SH, Stankovic AK, Williams LO, Beck JC, Herndon JE, Snow-Bailey K, Prior TW, Matteson KJ, Wasserman LM, Cole EC, Stenzel TT: Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testing. J Mol Diagn 2003, 5:227-230 (Pubitemid 37407446)
35. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215
36. Schwartz M, Petersen KB, Gregersen N, Hinkel K, Newton CR: Prenatal diagnosis of alpha-1-antitrypsin deficiency using polymerase chain reaction (PCR): comparison of traditional RFLP methods with PCR used in combination with allele-specific oligonucleotides or RFLP analysis. Clin Genet 1989, 36:419-426 (Pubitemid 20000893)
37. Tazelaar JP, Friedman KJ, Kline RS, Guthrie ML, Farber RA: Detection of alpha 1-antitrypsin Z and S mutations by polymerase chain reaction-mediated site-directed mutagenesis. Clin Chem 1992, 38:1486-1488
38. Hejtmancik JF, Sifers RN, Ward PA, Harris S, Mansfield T, Cox DW: Prenatal diagnosis of alpha-1 antitrypsin deficiency by restriction fragment length polymorphisms, and comparison with oligonucleotide probe analysis. Lancet 1986, 2:767-770
39. Andresen BS, Knudsen I, Jensen PK, Rasmussen K, Gregersen N: Two novel nonradioactive polymerase chain reaction-based assays of dried blood spots, genomic DNA, or whole cells for fast, reliable detection of Z and S mutations in the alpha-1 antitrypsin gene. Clin Chem 1992, 38:2100-2107
40. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC, Markham AF: Analysis of any point mutation in DNA: the amplification refractory mutation systems (ARMS). Nucleic Acids Res 1989, 17:2503-2516 (Pubitemid 19103235)
41. DeMeo DL, Silverman EK: Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 2004, 59:259-264
42. Zehnbauer BA: Multiple endocrine neoplasia syndromes. Molecular Pathology in Clinical Practice. Edited by DGB Leonard, A Bagy, A Caliendo, K Kaul, VM Van Deerlin. New York, Springer-Verlag, 2007
43. Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield M, Ponder BAJ: A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995, 10:509-513
44. Petrukhin L, Dangel J, Vanderveer L, Costalas J, Bellacosa A, Grana G, Daly M, Godwin AK: The I1307K APC mutation does not predispose to colorectal cancer in Jewish Ashkenazi breast and breastovarian cancer kindreds. Cancer Res 1997, 57:5480-5484 (Pubitemid 28006751)
45. Dangel J, Wagner-Costalas J, Bove B, Vanderveer L, Itzen M, Daly M, Godwin AK: Novel germline BRCA1 mutation (155del4) in an African American with early-onset breast cancer. Hum Mut 1999, 14:545
46. Andrulis IL, Anton-Culver H, Beck J, Bove B, Boyd J, Buys S, Godwin AK, Hopper JL, Li F, Neuhausen SL, Ozcelik H, Peel D, Santella RM, Southey MC, van Orsouw NJ, Venter DJ, Vijg J, Whittemore AS; Cooperative Family Registry for Breast Cancer studies: Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mut 2002, 20:65-73
47. Code of Federal Regulations. The Clinical Laboratory Improvement Amendments (CLIA) 2007, 42 CFR Part 493
48. Association for Molecular Pathology statement: Recommendations for in-house development and operation of molecular diagnostic tests. Am J Clin Pathol 1999, 111:449-463
49. MM17-A Verification and Validation of Multiplex Nucleic-Acid Assays. The Clinical and Laboratory Standards Institute (CLSI). 2nd ed. Wayne PA, CLSI, 2008
50. MM01-A2 Molecular Diagnostic Methods for Genetic Diseases-Approved Guideline. The Clinical and Laboratory Standards Institute (CLSI). Wayne PA, CLSI, 2006
51. Williams LO, Cole EC, Lubin IM, Iglesias NI, Jordan RL, Elliott LE: Quality assurance in human molecular genetics testing: status and recommendations. Arch Pathol Lab Med 2003, 127:1353-1358 (Pubitemid 37248336)
52. Fagerhol MK, Braend M: Serum prealbumin: polymorphism in man. Science 1965, 149:986-987